Pfizer Medical Information

Health Care Professionals Log In

Acromegaly Treatment Goals:

For you, blocking GH action to gain IGF-I control 7
For your patient, overall symptom improvement1

Consider your goal of controlling acromegaly, and your patients' desire for relief from disease signs and symptoms. SOMAVERT® has been shown to block growth hormone action, normalize IGF-I levels, and improve the overall signs and symptoms of acromegaly in a majority of patients in clinical trials.1 Take a look to learn about SOMAVERT and:

  • Efficacy
    SOMAVERT normalized
    IGF-I levels in a majority of patients, sustained normal levels over time... and, achieved clinically significant improvement of signs and symptoms.1
  • Tumor Data
    Overall mean tumor size remained unchanged in clinical trials.1

Moving forward with SOMAVERT®

Patient Profile

John, on SOMAVERT
since 2009

ACROSTUDY

Global safety surveillance
database of SOMAVERT patients open to all interested investigators

Pfizer Bridge Program®

Comprehensive, dedicated,
one-on-one support to
help your patients get on therapy fast and stay on

SOMAVERT is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum IGF-I levels.

IMPORTANT SAFETY INFORMATION

SOMAVERT is contraindicated in patients with a history of hypersensitivity to any of its components.

Patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids.

Functional effects of increased GH are prevented by GH receptor blockade; therefore, patients on SOMAVERT should be carefully observed for the clinical signs and symptoms of a GH-deficient state.

Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT.

Important safety information regarding periodic tumor size monitoring

  • Tumors that secrete GH may expand and cause serious complications. All patients with GH-secreting tumors, including those receiving SOMAVERT, should be carefully monitored for changes in tumor volume.
  • Overall, mean tumor size was unchanged during the course of treatment in clinical studies.
  • Tumor volume change did not appear to be influenced by whether or not patients had previously received radiation therapy.

Important safety information regarding liver test monitoring

  • Monitor liver tests based on baseline values and changes during therapy according to the schedule in the full prescribing information.
  • ALT was >3X but <10X the upper limit of normal (ULN) in patients treated with SOMAVERT (1.2%) vs placebo (2.1%).
    • ALT and AST elevations occurred within 4 to 12 weeks after the start of therapy and did not appear to be related to the dose.
  • In clinical studies with SOMAVERT, 2 patients (0.8%) experienced elevations of ALT and AST serum concentrations >10X the upper limit of normal (ULN).

If a patient develops liver test elevations, or any other signs or symptoms of liver dysfunction while receiving SOMAVERT, please see Liver Tests section of full Prescribing Information.

The most common adverse events (>10% and at frequencies greater than placebo) in 1 of the 3 active treatment arms in a placebo-controlled study (N=112) included infection, pain, diarrhea, nausea, flu syndrome, abnormal liver function tests, and injection-site reaction.

Injection sites should be rotated daily to help prevent lipohypertrophy.

The maximum daily maintenance dose is 30 mg.